Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.

Çobanoğlu N., Özçelik U., Çakır E., Şişmanlar E., Pekcan S., Cinel G., ...More

Pediatric pulmonology, vol.55, pp.2302-2306, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55
  • Publication Date: 2020
  • Doi Number: 10.1002/ppul.24854
  • Journal Name: Pediatric pulmonology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.2302-2306
  • Keywords: cystic fibrosis, modulator drugs, national registry, TEZACAFTOR-IVACAFTOR
  • Bezmialem Vakıf University Affiliated: Yes


Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.